WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001036462) PROTEIN C DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/036462 International Application No.: PCT/US2000/028884
Publication Date: 25.05.2001 International Filing Date: 06.11.2000
Chapter 2 Demand Filed: 17.05.2001
IPC:
A61K 38/00 (2006.01) ,C12N 9/64 (2006.01)
Applicants: GERLITZ, Bruce, Edward[US/US]; US (UsOnly)
GRINNELL, Brian, William[US/US]; US (UsOnly)
HUANG, Lihua[CN/US]; US (UsOnly)
JONES, Bryan, Edward[US/US]; US (UsOnly)
ELI LILLY AND COMPANY[US/US]; Lilly Corporate Center Indianapolis, IN 46285, US (AllExceptUS)
Inventors: GERLITZ, Bruce, Edward; US
GRINNELL, Brian, William; US
HUANG, Lihua; US
JONES, Bryan, Edward; US
Agent: BARRETT, Brian, P. ; Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285, US
Priority Data:
60/166,62319.11.1999US
Title (EN) PROTEIN C DERIVATIVES
(FR) DERIVES DE PROTEINE C
Abstract:
(EN) Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.
(FR) L'invention concerne de nouveaux dérivés de la protéine C humaine. Ces dérivés présentent une activité d'anticoagulation accrue comparés à la protéine C du type sauvage et maintiennent l'activité biologique de la protéine C du type sauvage. Ces dérivés nécessitent une administration moins fréquente et/ou un dosage moins important que la protéine C de type sauvage dans le traitement de syndromes coronaires aigus, de troubles occlusifs vasculaires, d'états hypercoagulants, de troubles thrombotiques et d'états de santé prédisposant à la thrombose.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)